StageOther Investors | Alive
Missing: tulex's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: tulex's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest tulex News
Mar 15, 2023
Delmaine Donson Terms of the transaction were not disclosed, currently. ET-600 is being developed to treat an endocrinology condition that is estimated to impact less than 5K children in the U.S., according to the company. "As a rare disease product that builds on our established presence in pediatric endocrinology, ET-600 is a perfect strategic fit for our portfolio," said Eton CEO Sean Brynjelsen. Eton expects to file a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the therapy in Q2 2024, which could allow for an approval and launch of the product in early 2025. Recommended For You
tulex Frequently Asked Questions (FAQ)
When was tulex founded?
tulex was founded in 2005.
What is tulex's latest funding round?
tulex's latest funding round is Other Investors.
Who are the investors of tulex?
Investors of tulex include High-Tech Grunderfonds and Sirius Venture Partners.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.